Ovarian cancer is one of the most lethal gynecologic malignancies for women. Due to the lack of efficient target therapy, the overall survival rate for patients with advanced ovarian cancer is still low. Illustrating the molecular mechanisms dictating ovarian cancer progression is critically important to develop novel therapeutic agents. Here, we found that RNA-binding motif protein 11 (RBM11) was highly elevated in ovarian cancer tissues compared with normal ovary, while RBM11 depletion in ovarian cancer cells resulted in impaired cell growth and invasion. Moreover, knockdown of RBM11 also retarded tumor growth in the A2780 ovarian cancer xenograft model. Mechanically, we found that RBM11 positively regulated Akt/mTOR signaling pathway activation in ovarian cancer cells. Thus, these results identify RBM11 is a novel oncogenic protein and prognostic biomarker for ovarian cancers.

中文翻译：

---

RNA 结合基序蛋白 11 (RBM11) 作为预后生物标志物并促进卵巢癌进展

卵巢癌是女性最致命的妇科恶性肿瘤之一。由于缺乏有效的靶向治疗，晚期卵巢癌患者的总体生存率仍然很低。阐明指示卵巢癌进展的分子机制对于开发新的治疗药物至关重要。在这里，我们发现与正常卵巢相比，卵巢癌组织中的 RNA 结合基序蛋白 11 (RBM11) 高度升高，而卵巢癌细胞中 RBM11 的消耗导致细胞生长和侵袭受损。此外，RBM11 的敲低也延缓了 A2780 卵巢癌异种移植模型中的肿瘤生长。机械地，我们发现 RBM11 正向调节卵巢癌细胞中 Akt/mTOR 信号通路的激活。因此，